Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
401
Dec 29, 2008
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to...
426
Dec 14, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
440
Dec 10, 2008
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
Myeloma X Relapse NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Multiple Myeloma RRMM - Myeloma X Relapse Time Frame:...
50
Dec 6, 2008
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
ECOG-E1A06 ECOG-ACRIN Cancer Research Group NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating...
67
Dec 3, 2008
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma A Study of...
51
Dec 3, 2008
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
65